Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ezgi B. Ulas"'
Autor:
Ezgi B. Ulas, BSc, Sayed M.S. Hashemi, MD, Ilias Houda, MD, Adem Kaynak, MSc, Joris D. Veltman, MD, PhD, Marieke F. Fransen, PhD, Teodora Radonic, MD, PhD, Idris Bahce, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 9, Pp 100532- (2023)
Introduction: In advanced-stage NSCLC, tumor proportion score (TPS) is typically used to predict the efficacy of immune checkpoint inhibitors (ICIs). Nevertheless, in other cancer types, the combined positive score (CPS), which covers programmed deat
Externí odkaz:
https://doaj.org/article/e19f82a0ac474b54adcefd75bbe9d1ac
Autor:
Mehrdad Rakaee, Elio Adib, Biagio Ricciuti, Lynette M. Sholl, Weiwei Shi, Joao V. Alessi, Alessio Cortellini, Claudia A. M. Fulgenzi, Patrizia Viola, David J. Pinato, Sayed Hashemi, Idris Bahce, Ilias Houda, Ezgi B. Ulas, Teodora Radonic, Juha P. Väyrynen, Elin Richardsen, Simin Jamaly, Sigve Andersen, Tom Donnem, Mark M. Awad, David J. Kwiatkowski
Publikováno v:
JAMA Oncology, 9(1), 51-60. American Medical Association
Rakaee, M, Adib, E, Ricciuti, B, Sholl, L M, Shi, W, Alessi, J V, Cortellini, A, Fulgenzi, C A M, Viola, P, Pinato, D J, Hashemi, S, Bahce, I, Houda, I, Ulas, E B, Radonic, T, V?yrynen, J P, Richardsen, E, Jamaly, S, Andersen, S, Donnem, T, Awad, M M & Kwiatkowski, D J 2023, ' Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC ', JAMA Oncology, vol. 9, no. 1, pp. 51-60 . https://doi.org/10.1001/jamaoncol.2022.4933
Rakaee, M, Adib, E, Ricciuti, B, Sholl, L M, Shi, W, Alessi, J V, Cortellini, A, Fulgenzi, C A M, Viola, P, Pinato, D J, Hashemi, S, Bahce, I, Houda, I, Ulas, E B, Radonic, T, V?yrynen, J P, Richardsen, E, Jamaly, S, Andersen, S, Donnem, T, Awad, M M & Kwiatkowski, D J 2023, ' Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC ', JAMA Oncology, vol. 9, no. 1, pp. 51-60 . https://doi.org/10.1001/jamaoncol.2022.4933
ImportanceCurrently, predictive biomarkers for response to immune checkpoint inhibitor (ICI) therapy in lung cancer are limited. Identifying such biomarkers would be useful to refine patient selection and guide precision therapy.ObjectiveTo develop a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a6d0febc37ee77d1b041f50df5fcc11
https://research.vumc.nl/en/publications/bf87beb5-16ad-466d-9519-a7e96a470fe3
https://research.vumc.nl/en/publications/bf87beb5-16ad-466d-9519-a7e96a470fe3
Autor:
Ezgi B. Ulas, Sayed M.S. Hashemi, Ilias Houda, Adem Kaynak, Joris D. Veltman, Marieke F. Fransen, Teodora Radonic, Idris Bahce
Publikováno v:
JTO Clinical and Research Reports. :100532
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a7c923d43e03362c65165b2c23e9a5f
https://doi.org/10.1016/j.jtocrr.2023.100532
https://doi.org/10.1016/j.jtocrr.2023.100532
Autor:
Tanja D de Gruijl, Lilian J Meijboom, Teodora Radonic, Chris Dickhoff, Idris Bahce, Sayed M S Hashemi, Daniela E Oprea-Lager, Ezgi B Ulas, Suresh Senan, Famke L Schneiders, Joris Veltman, David J Heineman, Anne Vrijmoet, Ilias Houda, Joyce Bakker, Peter van de Ven, Natalja Bouwhuis, Febe van Maldegem, Marieke F Fransen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 9 (2024)
Background In non-small cell lung cancer (NSCLC), chemoradiotherapy (CRT) yields pathological complete response (pCR) rates of approximately 30%. We investigated using ipilimumab plus nivolumab (IPI-NIVO) with neoadjuvant CRT in resectable, and borde
Externí odkaz:
https://doaj.org/article/f70d8187e5304db89a6c5551cdddd8e7
Autor:
Tanja D de Gruijl, Teodora Radonic, Marc C Huisman, Idris Bahce, Johanna E E Pouw, Sayed M S Hashemi, Jessica E Wijngaarden, Maarten Slebe, Daniela E Oprea-Lager, Gerben J C Zwezerijnen, Danielle Vugts, Ezgi B Ulas, Suresh Senan, C Willemien Menke-van der Houven van Oordt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)
Background In patients with locally advanced unresectable non-small cell lung cancer (NSCLC), durvalumab, an anti-programmed cell death ligand-1 (PD-L1) antibody, has shown improved overall survival when used as consolidation therapy following concur
Externí odkaz:
https://doaj.org/article/4b3a18abdb6f4a34986c4c57af3d9db7